INHIBITOR OF CELL PROLIFERATION IN OBINUTUZUMAB RESISTANT CD20-POSITIVE CANCER, AND MEDICINAL COMPOSITION, MEDICINE, PRODUCTION, METHOD FOR INHIBITING CELL PROLIFERATION, THERAPEUTIC METHOD, TYPE II ANTI-CD20 ANTIBODY, COMPOUNDS, COMBINATION OF SAME, ENHANCER AND INDUCER, EACH RELATING THERETO

There are cases of CD20-positive cancer where the cancer is tolerant to obinutuzumab and cases where the cancer recurs after an obinutuzumab-containing treatment.For CD20-positive cancer that is tolerant to obinutuzumab or CD20-positive cancer that has recurred following an obinutuzumab-containing t...

Full description

Saved in:
Bibliographic Details
Main Authors OKA, Natsumi, FUJIMURA, Takaaki, KASHIMA, Yoriko
Format Patent
LanguageEnglish
Published 15.02.2024
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:There are cases of CD20-positive cancer where the cancer is tolerant to obinutuzumab and cases where the cancer recurs after an obinutuzumab-containing treatment.For CD20-positive cancer that is tolerant to obinutuzumab or CD20-positive cancer that has recurred following an obinutuzumab-containing treatment, a type II anti-CD20 antibody is used in combination with one or more compounds selected from the group consisting of prednisolone, doxorubicin, vincristine, and salts and prodrugs thereof. Among these compounds, prednisolone, doxorubicin, and salts and prodrugs thereof may be selected. Furthermore, among these compounds, prednisolone or a salt or prodrug thereof may be selected.
Bibliography:Application Number: US202017766280